The conjugate vaccine market hit $23.84 billion in 2026 and is on a trajectory toward $38.54 billion by 2035, which makes the timing of Intravacc and SynphaBase’s new partnership less coincidental and more calculated. The deal connects two specific bottlenecks that have long frustrated conjugate vaccine developers: reliable access to high-quality synthetic oligosaccharides and the downstream conjugation and GMP manufacturing expertise needed to turn those materials into a clinical-stage product. Solving one without the other leaves developers stranded mid-pipeline.
The structural logic here is straightforward. SynphaBase brings glycochemistry depth, covering custom synthesis, process development, and regulatory support for the synthetic oligosaccharides that serve as the carbohydrate antigens in conjugate vaccines. Intravacc contributes conjugation process development, scale-up, and GMP production, capabilities it has already deployed across multiple vaccine programs. Together, they offer a vendor arrangement that takes a developer from raw synthetic antigen supply through to clinical manufacturing without forcing that developer to independently source and coordinate two specialist contractors. The partnership is non-exclusive, meaning both companies remain free to work with other parties, which limits lock-in risk for clients but also caps the strategic depth of the arrangement.
What gives this deal more than routine CDMO-partnership weight is the specific technical gap it targets. Synthetic oligosaccharides are a precision input: the chemistry is complex, the regulatory documentation requirements are exacting, and mistakes at this stage ripple forward into every subsequent manufacturing batch. Intravacc has been actively building out its conjugate platform, having renewed its conjugate-focused partnership with Primrose Bio for next-generation manufacturing approaches. Adding SynphaBase expands the front end of that platform rather than duplicating what already exists. The result is a more complete service stack for biotech sponsors who lack the in-house chemistry infrastructure to manage synthetic antigen supply independently.
The real test will be whether the integrated offering accelerates IND-enabling timelines for clients in practice, not just on paper. Watch Intravacc’s disclosure of new conjugate vaccine client programs over the next 12 months. A meaningful uptick in externally sponsored programs using both SynphaBase materials and Intravacc’s GMP capabilities would confirm that the partnership is generating commercial pull, not just a preferred-supplier arrangement that looks good in a press release.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
